Natalia Pijas

Natalia Pijas

Auto-generated profile, based on publicly available information

Natalia Pijas

Student’s Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
NPNatalia Pijas
Natalia Pijas
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
BPBarbara Pieniążek
Barbara Pieniążek
DPDaria Piekarz
Daria Piekarz
JSJolanta Szeliga-Król
Jolanta Szeliga-Król
WZWojciech Załuska
Wojciech Załuska
Introduction and objective: Chronic kidney disease (CKD) is a major health issue worldwide affecting 10–14% of the globe’s population, with a climbing trend. CKD is associated with a variety of factors, including obesity, which has grown increasingly prevalent and adds to the pathogenesis...

15 January 2026 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
MBMargareta Budner
Margareta Budner
MPMarcelina Podleśna
Marcelina Podleśna
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
NPNatalia Pijas
Natalia Pijas
KZKatarzyna Zyska
Katarzyna Zyska
ASAgnieszka Surowiecka
Agnieszka Surowiecka
Background/Objectives: Cleft lip and/or palate are common craniofacial anomalies whose surgical repair is classified as clean-contaminated and may be complicated by surgical site infection or palatal fistula. Despite widespread perioperative antibiotic use, there are no standardized, evidence-based recommendations, and rising antimicrobial resistance underlines the need for rational prescribing. This systematic scoping review aimed to map current evidence on prophylactic antibiotic therapy and related perioperative measures in cleft surgery. Methods: A scoping review was conducted using the Arksey and O’Malley framework and reported in line with PRISMA 2020. PubMed, Mendeley and Google Scholar were searched (January 2015–10 February 2025) for English-language retrospective studies, clinical trials, survey studies and systematic reviews concerning prophylactic antibiotics, bone grafting procedures, mouthwash use or oral microbiota in patients undergoing cleft lip and/or palate surgery. Six reviewers independently screened records; two experienced clinicians extracted data on study characteristics, antimicrobial regimens and infectious or microbiological outcomes. Given heterogeneity and the scoping aim, no formal risk-of-bias assessment or meta-analysis was performed. Results: A total of 40 studies met the inclusion criteria, including 21 original research articles. Considerable variation in antibiotic choice, timing and duration was observed, with no clear superiority of any regimen. Single-dose perioperative prophylaxis appeared non-inferior to prolonged courses in several settings. Oral microbiota studies highlighted colonization by resistant and opportunistic pathogens in cleft patients. Conclusions: Current evidence supports individualized, often short-course perioperative antibiotic strategies rather than routine prolonged therapy. High-quality randomized and microbiological studies are required to develop standardized, resistance-conscious guidelines.

31 December 2023 in OphthaTherapy. Therapies in Ophthalmology
Verified
Journal Article
Open access
PDF file
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
DPDaria Piekarz
Daria Piekarz
NPNatalia Pijas
Natalia Pijas
BPBarbara Pieniążek
Barbara Pieniążek
HPHalina Piecewicz-Szczęsna
Halina Piecewicz-Szczęsna
Uveal melanoma is the most common primary intraocular malignancy. In Europe, the incidence of uveal melanoma is approximately 8 cases per million people per year. In about 50% of cases, uveal melanoma metastasizes. Scientific papers on uveal melanoma published between 1 January 2018 – 1 March 2023, available in the PubMed database were analysed. Currently, methods such as enucleation, transpupillary thermotherapy, photodynamic therapy, eye plaque brachytherapy, proton beam therapy and stereotactic surgery are used to treat this cancer. In this paper we summarize the current knowledge about the classic treatment methods and the promising novel ones.

5 May 2026 in Medical Science Pulse
Verified
Journal Article
Closed access
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
NPNatalia Pijas
Natalia Pijas
DWDamian Wach
Damian Wach
MWMiłosz Włodarczyk
Miłosz Włodarczyk
PWPatrycja Wójcikiewicz
Patrycja Wójcikiewicz
KKKrzysztof Jerzy Kułak
Krzysztof Jerzy Kułak
Background: Ovarian cancer remains one of the most lethal gynecologic malignancies, ranking eighth in both incidence and mortality among women. Its asymptomatic early course and nonspecific symptoms often lead to late-stage diagnosis and a poor prognosis.Aim of the study: The aim of this article is to present the current status of immunotherapy in the treatment of ovarian cancer.Material and methods: A narrative review of the available literature was conducted, focusing on recent trials and studies evaluating immunotherapeutic approaches in ovarian cancer.Results: Standard treatment for ovarian cancer includes cytoreductive surgery followed by platinum-based chemotherapy; however, recurrence and platinum resistance remain major clinical challenges. In recent years, immunotherapy has emerged as an actively investigated treatment strategy, particularly in platinum-resistant disease. Various strategies are under investigation, including immune checkpoint inhibitors, CAR T-cell therapies, and oncolytic viruses. PD-1/PD-L1 inhibitors have shown potential efficacy, especially in tumors expressing PD-L1, which may serve as a predictive biomarker for treatment response.Conclusions: Despite promising research results, the clinical benefits of immunotherapy in ovarian cancer remain limited. Future studies should focus on identifying reliable predictive biomarkers, optimizing combination therapies, and improving treatment efficacy while maintaining an acceptable safety profile.

4 June 2026 in Quality in Sport
Verified
Journal Article
Open access
KCKatarzyna Cencelewicz
Katarzyna Cencelewicz
PBPatrycja Bździuch
Patrycja Bździuch
BPBarbara Pieniążek
Barbara Pieniążek
Aleksandra DomańskaAleksandra Domańska
Aleksandra Domańska
NPNatalia Pijas
Natalia Pijas
DPDaria Piekarz
Daria Piekarz
Background. Dysmenorrhea, one of the most common gynecological problems, significantly reduces patients’ quality of life. Standard therapy is based on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives, however it is associated with adverse effects. Alternative treatment methods are being sought, including vitamin supplementation, particularly vitamin D and E. Aim. The aim of this study was to evaluate the role of vitamin D and E supplementation in dysmenorrhea. Material and methods. In March 2026, the PubMed database was searched. The following strategies were applied: (Dysmenorrhea OR "menstrual pain") AND ("Vitamin D" OR cholecalciferol OR "vitamin D3" OR "25-hydroxyvitamin D" OR 25(OH)D) and (Dysmenorrhea OR "menstrual pain") AND ("Vitamin E" OR tocopherol OR alpha-tocopherol). Studies published in English within the last 10 years were included. After screening titles and abstracts, full-text analysis was performed. Ultimately, 12 publications were included. Results. An association between vitamin D levels and the severity of menstrual pain was demonstrated, and supplementation led to symptom reduction. Beneficial effects were also observed with the combined use of vitamins D and E, suggesting a possible synergistic effect. The results regarding vitamin E are inconsistent - some studies indicate its effectiveness, particularly in combination with other compounds (e.g., omega-3 fatty acids or vitamin C), which may be related to its antioxidant properties. However, not all studies confirm this relationship. Conclusions. Vitamin D and E supplementation may be an effective adjunct in the treatment of dysmenorrhea. However, further studies on larger populations are required.